Autoimmunity BioSolutions (ABS) is a Houston-based, seed-stage biotech developing genetically guided immuno-corrective therapies for autoimmune disease. Its lead program is a first-in-class series of monoclonal antibodies that target soluble IL7 receptor (sIL7R) while sparing membrane-bound IL7R, aiming to reduce autoreactive T-cell expansion and reset immune homeostasis rather than broadly suppress the immune system. The approach targets patients carrying a common single-nucleotide polymorphism, present in roughly half the population, that raises circulating sIL7R and is linked to worse disease severity and poor response to standard therapies. The company was founded on research from Drs. Gaddiel Galarza-Munoz and Mariano A. Garcia-Blanco and has raised $3.1 million in seed capital led by Eos BioInnovation.